Stocktwits on MSN
How Merck is preparing for the patent cliff of its blockbuster cancer drug Keytruda
Merck posted a modest Q4 earnings beat with adjusted EPS of $2.04 on $16.4 billion in revenue. ・The company is planning ...
Q4 2025 earnings call highlights: 2026 guidance, KEYTRUDA LOE risks, $70B pipeline outlook, and new launches—read now.
Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results